Hims acquires Eucalyptus

Hims & Hers, the telehealth company, has announced its acquisition of digital health provider Eucalyptus for a transaction valued at up to $1.15 billion. This acquisition aims to significantly enhance Hims & Hers' international market presence, marking a strategic shift as the company looks to offset domestic challenges by expanding into key markets such as Australia, Japan, the United Kingdom, Germany, and Canada. The move, using a phased payment structure, indicates the company's confidence in capturing growth opportunities abroad.

The deal includes an initial cash payment of $240 million, with additional payments planned across 18 months and performance-based earn-outs stretching to early 2029. The agreement allows up to 60% of future payments to be settled through Hims & Hers stocks, mitigating financial risks associated with the acquisition. Eucalyptus, which reported an annualized revenue run rate exceeding $450 million and triple-digit growth in 2025, will add significant customer reach, with its brands Juniper and Pilot boasting over 775,000 users. Tim Doyle, CEO of Eucalyptus, will assume the role of Senior Vice President of International operations post-merger.

The acquisition comes at a critical time for Hims & Hers, as it seeks to counterbalance growing regulatory pressures in the U.S. The company recently faced a setback by withdrawing a compounded oral semaglutide following an FDA warning, and is dealing with a patent lawsuit from Novo Nordisk concerning compounded medications. These challenges have driven Hims & Hers stock to a 52-week low, exacerbating investor concerns ahead of its financial results announcement for Q4 2025, scheduled for February 23, 2026.

By acquiring Eucalyptus, Hims & Hers aims to diversify revenue streams and lessen dependency on its U.S. operations amid heightened regulatory scrutiny. The acquisition serves as both a growth mechanism and a risk diversification strategy in a volatile sector as competitors also navigate stringent regulatory landscapes.

As Hims & Hers prepares for the integration of Eucalyptus, the focus will be on regulatory approvals and the seamless merger of operations. Investor sentiments and strategic direction will likely hinge on the outcome of its financial disclosures and the success of its international expansion strategy. The company's ability to leverage Eucalyptus's customer base and growth metrics effectively will be pivotal in assuaging concerns and capitalizing on global telehealth opportunities.